United Kingdom Benign Prostatic Hyperplasia Treatment Market Size
United Kingdom Benign Prostatic Hyperplasia Treatment Market size is projected at USD 844.00 million in 2026 and is expected to hit USD 1,355.13 million by 2034 with a CAGR of 6.10%. The market was valued at USD 795.50 million in 2025, indicating a USD 48.50 million year-on-year increase into 2026. Assessment of treatment categories, care settings, patient cohorts, distribution channels and competitive positioning is essential for evaluating the 2026–2034 opportunity.
Key Takeaways
- Pharmacological treatment dominates treatment type with USD 337.46 million in 2026, equivalent to approximately 39.98%, while minimally invasive procedures record the fastest 2026–2034 CAGR at 6.25%.
- Hospitals dominate end use at USD 378.93 million in 2026, representing approximately 44.88% of the USD 844.36 million end-use total.
- Ambulatory surgical centres are the fastest-growing end-use category with a 6.29% CAGR, reaching USD 261.17 million by 2034.
- Surgical treatment advances from USD 215.05 million in 2026 to USD 346.40 million in 2034 at 6.14%, while minimally invasive procedures increase from USD 207.17 million to USD 336.47 million.
- The supplied dataset covers the United Kingdom only; therefore, no separate emerging-country forecast, market value or CAGR can be calculated without introducing unsupported assumptions.
The market encompasses pharmacological management, TURP and other surgery, laser procedures, minimally invasive technologies and conservative approaches for benign prostate enlargement. As a healthcare-treatment market, standardized UK production volumes are not reported in the supplied dataset; measured treatment value rises from USD 795.50 million in 2025 to USD 844.00 million in 2026. Pharmacological treatment contributes 39.98% of the treatment-type total, surgical treatment 25.48%, minimally invasive procedures 24.55% and other treatments approximately 9.99%. NICE identifies UroLift for patients aged 50 years or older with prostate volumes of 30–80 ml, while Rezūm is recommended particularly for moderate-to-severe LUTS and prostates typically measuring 30–80 cm³.
Explore more data points, trends and opportunities Download Free Sample Report
United Kingdom Benign Prostatic Hyperplasia Treatment Market Trends
Shift Toward Minimally Invasive and Day-Case BPH Procedures
Technology adoption is moving treatment pathways toward interventions designed to reduce hospitalisation and preserve sexual function. NICE states that UroLift can be performed as a day-case or outpatient procedure in people aged 50+ with prostate volumes of 30–80 ml, with estimated 5-year savings of £981 versus bipolar TURP, £1,242 versus monopolar TURP and £1,230 versus HoLEP.
Water-vapour therapy is reinforcing this shift. Rezūm delivers steam in 9-second injections, allows up to 15 injections per delivery device and typically takes up to 20 minutes in NHS practice; NICE estimates savings exceeding £550 per patient over 4 years versus standard treatments. Boston Scientific reports a 4.4% surgical retreatment rate through 5 years and a 10.4-point sustained IPSS improvement.
United Kingdom Benign Prostatic Hyperplasia Treatment Market Drivers
Ageing Patient Pool and Broader Treatment Choice Support Intervention Volumes
BPH becomes increasingly relevant with advancing age, supporting sustained utilisation across pharmaceutical and procedural pathways. NICE-recognised options span at least 8 NHS treatments for significant LUTS, while UroLift evidence demonstrates symptom benefits extending to 5 years and Rezūm evidence shows benefits maintained for 4 years. For Rezūm, NHS clinical experts reported that around two-thirds of procedures were performed under general anaesthetic despite its suitability for local anaesthesia with sedation.
United Kingdom Benign Prostatic Hyperplasia Treatment Market Restraints
Clinical Eligibility and Reintervention Considerations Limit Universal Procedure Adoption
Treatment selection remains constrained by prostate anatomy, symptom severity, comorbidities and evidence maturity. Rezūm guidance typically targets prostate volumes of 30–80 cm³ and IPSS scores of 13 or above, while UroLift guidance covers patients aged 50+ and 30–80 ml prostates. Transperineal laser ablation remains restricted to special arrangements or research in defined populations because NICE found evidence from only 11 sources, including 2 randomised trials and 7 prospective case series.
United Kingdom Benign Prostatic Hyperplasia Treatment Market Opportunities
Day-Case Technologies Expand Capacity and Cost-Efficiency Potential
Day-case delivery creates opportunities to move appropriate patients away from resource-intensive inpatient pathways. UroLift can generate estimated 5-year per-patient savings of £981–£1,242 against selected TURP/HoLEP comparators, while Rezūm is estimated to save more than £550 over 4 years. Prostatic artery embolisation can also avoid general anaesthesia and may be performed as a day case, widening the procedural portfolio available to suitable patients.
Challenges in United Kingdom Benign Prostatic Hyperplasia Treatment Market
Evidence Requirements and Procedure-Specific Expertise Create Adoption Barriers
Technology diffusion requires training, governance and long-term evidence. NICE specifies that prostatic artery embolisation should involve both a urologist and interventional radiologist and be performed by appropriately trained specialists. For transperineal laser ablation, NICE reviewed 11 evidence sources 2 randomised trials, 2 systematic reviews and 7 prospective case series and still called for additional evidence on patient selection and long-term reintervention.
Report Scope
| Report Metric | Details |
|---|---|
| Market Size in 2025 | USD 795.5 Million |
| Market Size in 2026 | USD 844 Million |
| Market Size in 2034 | USD 1355.13 Million |
| CAGR | 6.1% (2026-2034) |
| Base Year for Estimation | 2025 |
| Historical Data | 2022-2024 |
| Forecast Period | 2026-2034 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Supply Chain Disruption, Growth Factors, Environment & Regulatory Landscape and Trends |
Explore more data points, trends and opportunities Download Free Sample Report
United Kingdom Benign Prostatic Hyperplasia Treatment Market Segmentation
Treatment segmentation demonstrates a comparatively balanced procedural landscape alongside pharmaceutical leadership. In 2026, pharmacological treatment accounts for approximately 39.98%, surgical treatment 25.48%, minimally invasive procedures 24.55% and other treatments 9.99% of the USD 844.00 million treatment-type total.
By Treatment Type
Pharmacological treatment is the largest category, increasing from USD 318.36 million in 2025 to USD 337.46 million in 2026 and USD 537.86 million by 2034 at a 6.00% CAGR. It includes alpha-blockers such as tamsulosin, silodosin, alfuzosin and doxazosin; 5-ARIs including dutasteride and finasteride; combination therapies; PDE5 inhibitors; and other drugs.
Minimally invasive procedures are the fastest-growing treatment category at 6.25%, expanding from USD 207.17 million in 2026 to USD 336.47 million by 2034. Surgical treatment grows at 6.14% to USD 346.40 million, while other treatments advance at 6.00% to USD 134.40 million.
By End Use
Hospitals are the largest end-use segment, valued at USD 378.93 million in 2026 versus USD 356.54 million in 2025, and are projected to reach USD 616.84 million by 2034 at a 6.28% CAGR. Hospitals consequently account for approximately 44.88% of the USD 844.36 million 2026 end-use total.
Ambulatory surgical centres are the fastest-growing end-use category at 6.29%, rising from USD 160.32 million in 2026 to USD 261.17 million in 2034. Clinics expand at 5.87% to USD 347.32 million, while specialty urology centers reach USD 135.15 million at a 5.96% CAGR.
By Patient Age Group
The segmentation covers below 50 years, 50–60 years and above 60 years. Numerical values or CAGRs for these 3 cohorts were not supplied, so allocating the USD 844.00 million 2026 total or USD 1,355.13 million 2034 total among them would require unsupported assumptions.
Clinical eligibility nevertheless highlights age-related differentiation: UroLift guidance explicitly covers people aged 50+ with prostate volumes of 30–80 ml, while the Rezūm pivotal evidence cited by Boston Scientific involved 197 subjects aged at least 50 years with IPSS ≥13 and prostate volumes of 30–80 cc.
By Distribution Channel
Hospital pharmacy, retail pharmacy and online pharmacy form the 3 distribution categories. Channel-specific values and CAGRs were not included in the mandatory dataset; consequently, no percentage allocation of the USD 337.46 million pharmacological-treatment value in 2026 or USD 537.86 million in 2034 is assigned.
The channel structure primarily applies to prescription pharmaceutical management rather than the USD 215.05 million surgical or USD 207.17 million minimally invasive categories in 2026. Alpha-blockers, 5-ARIs, combination therapies and PDE5 inhibitors represent the principal pharmaceutical classes within the supplied segmentation.
United Kingdom Benign Prostatic Hyperplasia Treatment Market Segmentations
By Treatment Type
-
Pharmacological treatment
-
Alpha-blockers
A PHP Error was encountered
Severity: Notice
Message: Undefined variable: segments
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Warning
Message: Invalid argument supplied for foreach()
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_once -
5-alpha reductase inhibitors (5-ARI)
A PHP Error was encountered
Severity: Notice
Message: Undefined variable: segments
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Warning
Message: Invalid argument supplied for foreach()
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_once -
Combination therapy
A PHP Error was encountered
Severity: Notice
Message: Undefined variable: segments
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Warning
Message: Invalid argument supplied for foreach()
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_once - Phosphodiesterase-5 inhibitors (pde5 inhibitors)
- Herbal and other drugs
-
Alpha-blockers
-
Surgical treatment
- Transurethral resection of the prostate (TURP)
- Transurethral incision of the prostate (TUIP)
- Open prostatectomy
-
Laser therapy
A PHP Error was encountered
Severity: Notice
Message: Undefined variable: segments
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Notice
Message: Trying to access array offset on value of type null
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_onceA PHP Error was encountered
Severity: Warning
Message: Invalid argument supplied for foreach()
Filename: reportpages/rd.php
Line Number: 419
Backtrace:
File: /var/www/skyintel/application/views/frontend/reportpages/rd.php
Line: 419
Function: _error_handlerFile: /var/www/skyintel/application/controllers/FrontendReportController.php
Line: 486
Function: viewFile: /var/www/skyintel/index.php
Line: 315
Function: require_once
-
Minimally invasive procedures
- Urolift system
- Rezūm water vapour therapy
- Prostatic artery embolisation
- Microwave thermotherapy
- Transurethral needle ablation (TUNA)
-
Other treatments
- Lifestyle modifications
- Watchful waiting / active surveillance
By End Use
- Hospitals
- Clinics
- Ambulatory surgical centres
- Specialty urology centers
By Patient Age Group
- Below 50 years
- 50–60 years
- Above 60 years
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
United Kingdom Benign Prostatic Hyperplasia Treatment Market Counties Outlook
England, Scotland, Wales and Northern Ireland collectively constitute the national opportunity. The supplied data provide only UK-level totals USD 795.50 million in 2025, USD 844.00 million in 2026 and USD 1,355.13 million in 2034 and provide no country-level percentages or production volumes; therefore, regional shares are not fabricated.
Across the United Kingdom, the 2026 treatment mix comprises USD 337.46 million pharmacological, USD 215.05 million surgical, USD 207.17 million minimally invasive and USD 84.32 million other treatment activity. NICE guidance applies within NHS decision frameworks, while HealthTech guidance including HTG737 is also endorsed by Healthcare Improvement Scotland.
Top players in United Kingdom's benign prostatic hyperplasia treatment market
- Boston Scientific Corporation
- Teleflex Incorporated
- Olympus Corporation
- KARL STORZ SE & Co. KG
- Richard Wolf GmbH
- Cook Medical
- Coloplast A/S
- Bayer AG
- GSK plc
- Astellas Pharma Inc.
- Eli Lilly and Company
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Johnson & Johnson
Top Two Companies
- Boston Scientific Corporation:A leading procedural competitor through Rezūm water-vapour therapy and a broader urology portfolio. Rezūm targets prostates above 30 cc, has reported durable outcomes through 5 years and a 4.4% surgical retreatment rate at 5 years. NICE estimates the technology can save more than £550 per patient over 4 years versus TURP or HoLEP. A verified company-level percentage of total UK BPH-treatment revenue is not publicly disclosed in the reviewed evidence, so no unsupported % share is assigned.
- Teleflex Incorporated:Teleflex is positioned prominently in minimally invasive BPH intervention through the UroLift System. NICE supports UroLift for people aged 50+ with prostate volumes of 30–80 ml and reports clinical benefits lasting up to 5 years. Its economic model estimates savings of £981 versus bipolar TURP, £1,242 versus monopolar TURP and £1,230 versus HoLEP over 5 years when delivered as a day case. No audited UK company-level revenue percentage is available in the reviewed sources; accordingly, no speculative % share is stated.
Recent Developments in United Kingdom Benign Prostatic Hyperplasia Treatment Market
- 2026:NICE migrated prostate artery embolisation guidance to HTG469 in January 2026 without changing the underlying recommendations.
- 2026:NICE migrated transperineal laser ablation guidance to HTG737 in January 2026; evidence-generation requirements remained in place.
- 2025:NICE migrated UroLift guidance to HTG578 in December 2025, retaining recommendations supporting use in patients aged 50+ with 30–80 ml prostates.
- 2025:Rezūm guidance moved to HTG545 in December 2025 with recommendations unchanged, including the 30–80 cm³ typical prostate range.
- 2025:NICE published guidance on transperineal laser ablation on 8 January 2025, based on evidence including 2 randomised controlled trials, 2 systematic reviews and 7 prospective case series.
Research Methodology
The analysis uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast horizon, with 2022–2024 treated as historical years. Mandatory supplied values were retained without substitution; percentage contributions were calculated directly from the supplied 2026 totals. Secondary validation used NICE HealthTech guidance and manufacturer clinical evidence for procedure duration, eligibility, clinical outcomes and technology developments. No unsupported county, age-group, distribution-channel or company percentage was imputed where numerical source data were unavailable.
Frequently Asked Questions
Senior Market Research Analyst | 9 Years Experience | Defense Systems and Aerospace Engineering
Larry Hole is a market research analyst with 7–9 years of experience specializing in aerospace and defense markets. Contributed to 70+ research reports for global clients. Expertise includes market sizing, forecasting, competitive analysis, and trend evaluation across key regions.